While Novo Nordisk say they're fighting against stigma, critics say they could be promoting prescription drugs under the ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss therapy Wegovy, allowing its use against metabolic dysfunction-associated ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the ...

The new approval allows the GLP-1 to be used to treat adults with the liver disease metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. Wegovy is the first GLP-1 to receive ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

Decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a liver condition that affects around 5 per cent of ...

Asda Online Doctor said it had seen a 350 per cent increase in demand for Mounjaro since Lilly announced the price rise on Thursday, while London-based MedExpress said it had seen a 40 per cent jump ...